UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 29, 2007
Molecular Pharmacology (USA) Limited
(Exact name of Registrant as specified in charter)
Nevada | 000-50156 | 71-0900799 |
(State or other jurisdiction
of incorporation) | (Commission
File Number) | (IRS Employer
Identification No.) |
| | | |
8721 Santa Monica Boulevard, Los Angeles, California | 90069-4507 |
(Address of principal executive offices) | (Zip Code) |
| | |
Registrant's telephone number, including area code: | 011-61-8-9443-3011 |
| | |
Not Applicable |
(Former name or former address if changes since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ___ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ___ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ___ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ___ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
This document includes "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Other than statements of historical fact, all statements regarding industry prospects, the consummation of the transactions described in this document and the Company's expectations regarding the future performance of its businesses and its financial position are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties.
ITEM 5.03 - CHANGES IN REGISTRANTS' CERTIFYING ACCOUNTANT
Fiscal Year End to Change From October 31st to June 30th
On March 15, 2007, the Board of Directors of Molecular Pharmacology (USA) Limited, a Nevada corporation (the "Registrant"), approved a change in the Registrant's financial year end from October 31st to June 30th. The report covering the transition period will be filed on Form 10-KSB on September 30, 2006.
The Board of Directors' decision to change the fiscal year-end is intended to assist the financial community in its analysis of the business and in comparing the Registrant's financial results to others in the industry, and to synchronize the Registrant's fiscal reporting period with the Registrant's Australian subsidiary company and parent company both of whom have a current year end of June 30, 2006.
A copy of the press release announcing the change in fiscal year is attached hereto as Exhibit 99.1
ITEM 9.01 - FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements of Business Acquired. N/A
(b) Pro forma financial information. N/A
(c) Exhibits.
As described in Item 5.02 of this Report, the following exhibit is filed as part of this Current Report on Form 8-K:
| | | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Press Release dated March 29, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE REGISTRANT
By:
/s/ Jeff Edwards
_________________________________
Jeff Edwards, Director
Dated: March 29, 2007
